- Home
- GMM vs CGTX Comparison
GMM vs CGTX Comparison
Compare GMM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMM | CGTX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 158.8M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GMM | CGTX |
|---|---|---|
| Price | $1.30 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 16.3K | ★ 942.9K |
| Earning Date | 08-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.72 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $0.22 |
| 52 Week High | $4.97 | $3.83 |
Technical Indicators
Market Signals| Indicator | GMM | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 53.10 |
| Support Level | $1.28 | $1.69 |
| Resistance Level | $1.41 | $1.77 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 12.82 | 75.58 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.